WO2019168289A1 - 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제 - Google Patents
벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제 Download PDFInfo
- Publication number
- WO2019168289A1 WO2019168289A1 PCT/KR2019/001894 KR2019001894W WO2019168289A1 WO 2019168289 A1 WO2019168289 A1 WO 2019168289A1 KR 2019001894 W KR2019001894 W KR 2019001894W WO 2019168289 A1 WO2019168289 A1 WO 2019168289A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eye drop
- amino
- pharmaceutically acceptable
- acceptable salt
- propylene glycol
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the present invention relates to eye drops in the form of a solution comprising a benzopyran derivative or a pharmaceutically acceptable salt thereof. More specifically, the present invention provides a benzopyran derivative or a pharmaceutically acceptable salt thereof; And specific stabilizers, and to eye drops in the form of a solution having a specific pH range.
- the benzopyran derivative of the formula (1) has the chemical name (2R, 3R, 4S) -6-amino-4- [N- (4-chlorophenyl) -N- (1H-imidazol-2-ylmethyl) amino]- It is 3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran and is known as a compound having therapeutic effects such as cancer and rheumatoid arthritis. 10-0492252).
- the compound of Formula 1 may be prepared as a low-molecular-based eye drop, and it is known that the compound may be useful for the prevention and treatment of macular degeneration without directly injecting the affected area, such as a protein antibody injection therapy ( Korean Patent Publication No. 10-2012-0112162).
- Korean Patent Publication No. 10-2012-0112162 discloses eye drops in the form of a solution or suspension, for example, using polyethylene glycol and glycerin as a solubilizer, the compound of formula 1 is 0.06 w / v% and Eye drops in the form of solutions containing at a concentration of 0.09 w / v% are disclosed.
- the inventors have conducted various studies to develop eye drops in solution form containing high concentrations of compounds of formula 1 (eg, concentrations of at least 3.0 mg / ml) in an aqueous medium and also having improved stability.
- the inventors of the present invention have found that when the pH of the solution is adjusted to a specific range (ie, pH 4.0 to pH 5.0) and the formulation is performed using a specific stabilizer (ie, propylene glycol), the compound of formula 1 is It has been found that eye drops in the form of solutions that contain and also have good stability can be prepared.
- the inventors have found that when the obtained eye drop is filled into a light-shielding container, a medicine which can be stored for a long time can be obtained.
- the present invention provides a compound of Formula 1 or a pharmaceutically acceptable salt thereof; And propylene glycol as a stabilizer, and to provide an eye drop in the form of a solution having a pH of 4.0 to 5.0.
- an object of the present invention is to provide a medicine for the prevention or treatment of macular degeneration obtained by filling the eye drop in the light-shielding container.
- the above (2R, 3R, 4S) -6-amino-4- [N- (4-chlorophenyl) -N- (1H-imidazol-2-ylmethyl) amino] -3- Hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof is at least 3 mg / ml, preferably 3 to 10 mg / may be present in a concentration of ml.
- the propylene glycol may be present at a concentration of 1 to 20 mg / ml, preferably 5 to 17 mg / ml, more preferably 10 to 15 mg / ml.
- the eye drop of the present invention may preferably have a pH of 4.2 to 4.7, more preferably a pH of about 4.5.
- Eye drops of the present invention may further comprise an additive selected from the group consisting of stabilizing aids, buffers, and preservatives.
- the stabilizing aid may be selected from one or more of the group consisting of ethylenediaminetetraacetic acid or a salt thereof and tromethamine.
- the buffer may be at least one selected from the group consisting of borax, boric acid, phosphate, citric acid, sodium citrate and aminocapronic acid.
- the preservative may be selected from the group consisting of benzalkonium chloride, chlorohexidine gluconate, sorbic acids, chlorobutanol and parabens.
- a medicament for preventing or treating macular degeneration obtained by filling the eye drop container with the eye drop.
- a medicament for preventing or treating macular degeneration according to the present invention may be obtained by filling the eye drop in a light-shielding container and then packaging in a paper case.
- Eye drops in solution form according to the invention can contain high concentrations of the compound of formula 1 as well as have good stability.
- the drug according to the present invention can be stored for a long time.
- eye drops and pharmaceuticals in the form of solutions according to the invention can be usefully used for the prevention or treatment of macular degeneration.
- Figure 2 is a result of evaluating the inhibitory effect on the pathogenic retinal angiogenesis of the eye drops of the present invention in macular degeneration animal model.
- the invention provides (2R, 3R, 4S) -6-amino-4- [N- (4-chlorophenyl) -N- (1H-imidazol-2-ylmethyl) amino] -3-hydroxy in aqueous medium.
- a pH adjusting agent wherein the eye drop in solution form has a pH of 4.0 to 5.0.
- the aqueous medium includes distilled water for injection, sterile purified water, physiological saline, and the like.
- the above (2R, 3R, 4S) -6-amino-4- [N- (4-chlorophenyl) -N- (1H-imidazol-2-ylmethyl) amino] -3- Hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran has the chemical structure of formula (1) as described above.
- the pharmaceutically acceptable salt of the compound of Formula 1 includes, without limitation, acid addition salts, alkali metal salts, alkaline earth metal salts, and the like, disclosed in Korean Patent Publication No. 10-2012-0112162.
- the compound of Formula 1 may be present at a concentration of 3 mg / ml or more, preferably 3 to 10 mg / ml.
- the propylene glycol is 1 to 20 mg / ml, preferably 5 to 17 mg / ml, more preferably 10 to 15 mg / ml, particularly preferably about 13 mg / ml (ie 12 to 14 mg / ml). May be present at a concentration of
- the eye drop of the present invention may preferably have a pH of 4.2 to 4.7, more preferably a pH of about 4.5 (ie, a pH of 4.4 to 4.6).
- the pH adjustment may be performed using a conventional pH adjusting agent used in the eye drop field, for example, hydrochloric acid and / or sodium hydroxide may be used as the pH adjusting agent, but is not limited thereto.
- Eye drops of the present invention may further comprise an additive selected from the group consisting of stabilizing aids, buffers, and preservatives.
- the amount of the additive used may be appropriately selected by those skilled in the art in consideration of the respective functions.
- the stabilizing adjuvant may be selected from the group consisting of ethylenediaminetetraacetic acid or salts thereof (eg, sodium salt, etc.) and tromethamine.
- the stabilizing aid may be used in the range of 0.05 to 10.0 mg / ml, but is not limited thereto.
- the buffer may be at least one selected from the group consisting of borax, boric acid, phosphates (sodium phosphate, sodium hydrogen phosphate, potassium phosphate, etc.), citric acid, sodium citrate and aminocapronic acid.
- the buffer may vary depending on the type but may be used in the range of 0.05 to 18.0 mg / ml.
- the preservatives include benzalkonium chloride, chlorhexidine digluconate, chlorobutanol, sorbic acids (e.g., sorbic acid, potassium sorbate, sodium sorbate, etc.) and parabens (e.g., methylparaben, propyl). Parabens and the like).
- the preservative may be used in the range of 0.01 to 0.5 mg / ml, but is not limited thereto.
- the eye drop of the present invention may be filled into an appropriate container after aseptic filtration with a bacterial filter such as, for example, a 0.2 ⁇ m membrane filter.
- Hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof 3-10 mg / ml; Propylene glycol 1-20 mg / ml; 0.01-1.0 mg / ml of ethylenediaminetetraacetic acid or salts thereof; Tromethamine 0.05-10.0 mg / ml; Borax 1.0-11.0 mg / ml; Boric acid 0.1-18.0 mg / ml; Benzalkonium chloride 0.01-0.5 mg / ml; And a pH adjusting agent, wherein the eye drop in the form of a solution is provided having a pH of 4.0 to 5.0.
- a pH adjusting agent wherein the eye drop in the form of a solution is provided having a pH of 4.0 to 5.0.
- the present invention also provides a medicament for preventing or treating macular degeneration obtained by filling the eye drop container with the eye drop.
- a medicament for the prevention or treatment of macular degeneration according to the present invention can be obtained by filling the eye drop in a light-shielding container and then packaging in a paper case.
- the light blocking container includes, but is not limited to, for example, a non-transparent low-density polyethylene container, a non-transparent polypropylene container, and the like.
- HL217 is (2R, 3R, 4S) -6-amino-4- [N- (4-chlorophenyl) -N- (1H-imidazol-2-ylmethyl ) Amino] -3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran.
- the concentration of HL217 was 0.3 w / v% (that is, Except for use at a concentration of 3.0 mg / ml), dissolution was carried out in the same manner to evaluate the manufacturability of eye drops in solution form.
- Reference Examples 2-1, 2-2, and 2-3 were respectively refrigerated condition (5 ⁇ 3 ° C.), room temperature condition (25 ⁇ 2 ° C., 40 ⁇ 5% RH), and accelerated condition (40 ⁇ 2 ° C.). , 25% RH) was stored for 4 weeks, the content of the flexible material was measured.
- the maximum soft substance content and the total soft substance content were measured by high performance liquid chromatography (HPLC) under the following conditions.
- Ammonium formate buffer solution prepared by adjusting 10 mM ammonium formate solution to pH 5.5 with phosphoric acid
- Example 1 (pH 4.5)
- Example 2 (pH 4.5) HL217 3.0 mg 3.0 mg Propylene glycol 13.0 mg 13.0 mg EDTA 0.5 mg 0.5 mg Tromethamine - 0.35 mg Boric acid 5.82 mg 5.82 mg borax 0.588 mg 0.588 mg Benzalkonium chloride 0.1 mg 0.1 mg HCl Quantity Quantity NaOH Quantity Quantity Constellation Clear solution Clear solution
- Example 3 (pH 4.5)
- Example 4 (pH 4.5) HL217 5.0 mg 10.0 mg Propylene glycol 13.0 mg 13.0 mg EDTA 0.5 mg 0.5 mg Tromethamine 0.35 mg 0.35 mg Boric acid 5.82 mg 5.82 mg borax 0.588 mg 0.588 mg Benzalkonium chloride 0.1 mg 0.1 mg HCl Quantity Quantity NaOH Quantity Quantity Constellation Clear solution Clear solution
- Example 5 (pH 4.5)
- Example 6 (pH 4.5)
- Example 7 (pH 4.5) HL217 3.0 mg 3.0 mg 3.0 mg Propylene glycol 1.0 mg 5.0 mg 20.0 mg EDTA 0.5 mg 0.5 mg 0.5 mg Tromethamine 0.35 mg 0.35 mg 0.35 mg Boric acid 5.82 mg 5.82 mg 5.82 mg borax 0.588 mg 0.588 mg 0.588 mg Benzalkonium chloride 0.1 mg 0.1 mg 0.1 mg 0.1 mg 0.1 mg 0.1 mg HCl Quantity Quantity Quantity NaOH Quantity Quantity Quantity Constellation Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear
- Example 5-7 The solutions of Examples 5-7 were respectively cooled for 4 weeks at refrigerated conditions (5 ⁇ 3 ° C.), room temperature conditions (25 ⁇ 2 ° C., 40 ⁇ 5% RH), and accelerated conditions (40 ⁇ 2 ° C., 25% RH). While storing, the content of the flexible substance was measured in the same manner as in (2) of Reference Example 2. The results are shown in Tables 13 to 15 below.
- Test group 1 The eye drop of Example 2 was filled and stored in a transparent LDPE container.
- Test group 2 The eye drop of Example 2 was charged and stored in an opaque LDPE container.
- Test group 3 The eye drop of Example 2 was filled in a transparent LDPE container and stored in a paper case.
- Test group 4 The eye drop of Example 2 was filled into an opaque LDPE container and stored in a paper case.
- Test group 1 Test group 2 Test group 3 Test group 4 Test group 1 Test group 2 Test group 3 Test group 4 Maximum Lead Material 0.30% 0.10% 0.03% 0.03% 0.72% 0.03% 0.03% 0.03% Total lead 1.11% 0.13% 0.03% 0.06% 3.43% 0.04% 0.06% 0.04%
- the HL217-containing eye drops are preferably filled in an opaque container, and more preferably, filled in an opaque container and stored in a paper case.
- the control group was instilled with 1 drop of sterile saline in both eyes twice daily for 3 weeks in 8 normal mice.
- AMD triggered group vldlr Gene knocked out mice ( vldlr Physiological saline was instilled 1 drop into both eyes twice daily for 3 weeks.
- Positive control vldlr -/-Lucentis on Mouse TM 1 ⁇ l of injection (containing 50 ng / ⁇ l of ranibizumab) was administered once into the intravitreal vitreous using a Hamiltion syringe (Hamilton company, Reno, NV, USA).
- the test group uses the eye drops of Example 2 vldlr Mice were instilled 1 drop in both eyes twice daily for 3 weeks.
- Hoechst 33342 (sigma) was injected into the left ventricle. After 10 minutes, the eye was removed, fixed in 4% paraformaldehyde for 2 hours, and the retina was separated. The detached retina was placed on a slide and inoculated with an aqueous mounting medium (Fluoromount TM , Sigma, St. Louis, Mo., USA) and observed under a fluorescence microscope. For quantitative analysis of tracer dyes, blood was collected from the heart 10 minutes after dye injection, perfused with sterile PBS to remove residual dye in the blood vessels, and the eyes were extracted to separate retinas.
- an aqueous mounting medium Fluoromount TM , Sigma, St. Louis, Mo., USA
- the separated retina was homogenized in 100 ⁇ L of PBS, and centrifuged to measure the amount of FITC-dextran on a spectrofluorophotometer using only the supernatant.
- the intensity of fluorescence was measured by excitation 485 nm and emission 530 nm, and calculated by calibrating the FITC fluorescence and retinal protein concentration in blood. The measurement results are shown in FIG. 1.
- mice As shown in FIG. 1, the border of blood vessels is clear in normal mice, and normal vascular integrity is well maintained. But vldlr In mice, fluorescent tracer dye injected into the blood vessel leaked out of the blood vessel (white arrow) to increase the retinal fluorescence intensity. Multiple leakage was observed, and local subretinal neovascularization area (red arrow) was observed. However, the eye treated with the eye drops of Example 2 inhibited vascular leakage and pathogenic angiogenesis. However, the positive control group showed significant efficacy at the 2nd week of drug administration.
- retinal angiogenic tufts (white arrows) were scattered in various places in the vldlr -/-mouse in isolelectin B4 staining. Decreased by administration of the eye drops of Example 2.
- vldlr -/-mice showed a large number of abnormal neovascularizations in the subretinal area (arrow area). Showed a tendency.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Food Science & Technology (AREA)
- Mechanical Engineering (AREA)
Abstract
Description
성분명 | 참조예 1 (pH 6.5) |
HL217 | 3.0 mg |
폴리에칠렌글리콜 400 | 150 mg |
글리세린 | 120 mg |
EDTA | 0.5 mg |
붕산 | 10 mg |
HCl | 적량 |
NaOH | 적량 |
성상 | 침전물 발생 |
성분명 | 참조예 2-1(pH 4.5) | 참조예 2-2(pH 4.5) | 참조예 2-3(pH 4.5) |
HL217 | 3.0 mg | 3.0 mg | 3.0 mg |
폴리에칠렌글리콜 400 | 15.0 mg | - | 15.0 mg |
글리세린 | 12.0 mg | 12.0 mg | 12.0 mg |
EDTA | 0.5 mg | 0.5 mg | 0.5 mg |
붕산 | 10.0 mg | 10.0 mg | 10.0 mg |
HCl | 적량 | 적량 | 적량 |
NaOH | 적량 | 적량 | 적량 |
성상 | 투명한 용액 | 투명한 용액 | 투명한 용액 |
보관조건 | 초기 | 2주 | 4주 | |
냉장 조건 | 최대 유연물질 | 0.32% | 0.99% | 1.24% |
총 유연물질 | 0.38% | 1.61% | 1.80% | |
실온 조건 | 최대 유연물질 | 0.32% | 1.37% | 2.16% |
총 유연물질 | 0.38% | 2.23% | 3.61% | |
가속 조건 | 최대 유연물질 | 0.32% | 2.14% | 2.61% |
총 유연물질 | 0.38% | 3.33% | 4.00% |
보관조건 | 초기 | 2주 | 4주 | |
냉장 조건 | 최대 유연물질 | 불검출 | 0.65% | 1.08% |
총 유연물질 | 불검출 | 1.15% | 1.53% | |
실온 조건 | 최대 유연물질 | 불검출 | 0.98% | 1.54% |
총 유연물질 | 불검출 | 1.56% | 2.85% | |
가속 조건 | 최대 유연물질 | 불검출 | 1.75% | 2.54% |
총 유연물질 | 불검출 | 2.53% | 3.38% |
보관조건 | 초기 | 2주 | 4주 | |
냉장 조건 | 최대 유연물질 | 0.36% | 1.10% | 1.35% |
총 유연물질 | 0.42% | 1.10% | 1.71% | |
실온 조건 | 최대 유연물질 | 0.36% | 1.52% | 1.79% |
총 유연물질 | 0.42% | 1.97% | 2.71% | |
가속 조건 | 최대 유연물질 | 0.36% | 2.54% | 3.01% |
총 유연물질 | 0.42% | 3.78% | 4.36% |
성분명 | 실시예 1(pH 4.5) | 실시예 2(pH 4.5) |
HL217 | 3.0 mg | 3.0 mg |
프로필렌글리콜 | 13.0 mg | 13.0 mg |
EDTA | 0.5 mg | 0.5 mg |
트로메타민 | - | 0.35 mg |
붕산 | 5.82 mg | 5.82 mg |
붕사 | 0.588 mg | 0.588 mg |
염화벤잘코늄 | 0.1 mg | 0.1 mg |
HCl | 적량 | 적량 |
NaOH | 적량 | 적량 |
성상 | 투명한 용액 | 투명한 용액 |
보관조건 | 초기 | 2주 | 4주 | |
냉장 조건 | 최대 유연물질 | 불검출 | 불검출 | 0.03% |
총 유연물질 | 불검출 | 불검출 | 0.03% | |
실온 조건 | 최대 유연물질 | 불검출 | 0.06% | 0.16% |
총 유연물질 | 불검출 | 0.09% | 0.21% | |
가속 조건 | 최대 유연물질 | 불검출 | 0.34% | 0.79% |
총 유연물질 | 불검출 | 0.66% | 1.62% |
보관조건 | 초기 | 2주 | 4주 | |
냉장 조건 | 최대 유연물질 | 불검출 | 불검출 | 0.04% |
총 유연물질 | 불검출 | 불검출 | 0.04% | |
실온 조건 | 최대 유연물질 | 불검출 | 0.07% | 0.18% |
총 유연물질 | 불검출 | 0.10% | 0.23% | |
가속 조건 | 최대 유연물질 | 불검출 | 0.36% | 0.88% |
총 유연물질 | 불검출 | 0.64% | 1.60% |
성분명 | 실시예 3(pH 4.5) | 실시예 4(pH 4.5) |
HL217 | 5.0 mg | 10.0 mg |
프로필렌글리콜 | 13.0 mg | 13.0 mg |
EDTA | 0.5 mg | 0.5 mg |
트로메타민 | 0.35 mg | 0.35 mg |
붕산 | 5.82 mg | 5.82 mg |
붕사 | 0.588 mg | 0.588 mg |
염화벤잘코늄 | 0.1 mg | 0.1 mg |
HCl | 적량 | 적량 |
NaOH | 적량 | 적량 |
성상 | 투명한 용액 | 투명한 용액 |
보관조건 | 초기 | 2주 | 4주 | |
냉장 조건 | 최대 유연물질 | 불검출 | 0.03% | 0.04% |
총 유연물질 | 불검출 | 0.03% | 0.04% | |
실온 조건 | 최대 유연물질 | 불검출 | 0.08% | 0.16% |
총 유연물질 | 불검출 | 0.10% | 0.22% | |
가속 조건 | 최대 유연물질 | 불검출 | 0.35% | 0.79% |
총 유연물질 | 불검출 | 0.67% | 1.63% |
보관조건 | 초기 | 2주 | 4주 | |
냉장 조건 | 최대 유연물질 | 불검출 | 0.03% | 0.04% |
총 유연물질 | 불검출 | 0.07% | 0.05% | |
실온 조건 | 최대 유연물질 | 불검출 | 0.07% | 0.15% |
총 유연물질 | 불검출 | 0.10% | 0.23% | |
가속 조건 | 최대 유연물질 | 불검출 | 0.33% | 0.89% |
총 유연물질 | 불검출 | 0.62% | 1.71% |
성분명 | 실시예 5(pH 4.5) | 실시예 6(pH 4.5) | 실시예 7(pH 4.5) |
HL217 | 3.0 mg | 3.0 mg | 3.0 mg |
프로필렌글리콜 | 1.0 mg | 5.0 mg | 20.0 mg |
EDTA | 0.5 mg | 0.5 mg | 0.5 mg |
트로메타민 | 0.35 mg | 0.35 mg | 0.35 mg |
붕산 | 5.82 mg | 5.82 mg | 5.82 mg |
붕사 | 0.588 mg | 0.588 mg | 0.588 mg |
염화벤잘코늄 | 0.1 mg | 0.1 mg | 0.1 mg |
HCl | 적량 | 적량 | 적량 |
NaOH | 적량 | 적량 | 적량 |
성상 | 투명한 용액 | 투명한 용액 | 투명한 용액 |
보관조건 | 초기 | 2주 | 4주 | |
냉장 조건 | 최대 유연물질 | 불검출 | 불검출 | 불검출 |
총 유연물질 | 불검출 | 불검출 | 불검출 | |
실온 조건 | 최대 유연물질 | 불검출 | 0.07% | 0.16% |
총 유연물질 | 불검출 | 0.09% | 0.21% | |
가속 조건 | 최대 유연물질 | 불검출 | 0.35% | 0.87% |
총 유연물질 | 불검출 | 0.64% | 1.66% |
보관조건 | 초기 | 2주 | 4주 | |
냉장 조건 | 최대 유연물질 | 불검출 | 불검출 | 불검출 |
총 유연물질 | 불검출 | 불검출 | 불검출 | |
실온 조건 | 최대 유연물질 | 불검출 | 0.06% | 0.16% |
총 유연물질 | 불검출 | 0.09% | 0.22% | |
가속 조건 | 최대 유연물질 | 불검출 | 0.34% | 0.79% |
총 유연물질 | 불검출 | 0.64% | 1.57% |
보관조건 | 초기 | 2주 | 4주 | |
냉장 조건 | 최대 유연물질 | 불검출 | 불검출 | 불검출 |
총 유연물질 | 불검출 | 불검출 | 불검출 | |
실온 조건 | 최대 유연물질 | 불검출 | 0.08% | 0.16% |
총 유연물질 | 불검출 | 0.14% | 0.20% | |
가속 조건 | 최대 유연물질 | 불검출 | 0.33% | 0.83% |
총 유연물질 | 불검출 | 0.62% | 1.56% |
보관방법 | |
시험군 1 | 실시예 2의 점안제를 투명 LDPE용기에 충전하여 보관 |
시험군 2 | 실시예 2의 점안제를 불투명 LDPE용기에 충전하여 보관 |
시험군 3 | 실시예 2의 점안제를 투명 LDPE용기에 충전하고, 종이케이스에 보관 |
시험군 4 | 실시예 2의 점안제를 불투명 LDPE용기에 충전하고, 종이케이스에 보관 |
자외선 | 가시광선 | |||||||
시험군 1 | 시험군 2 | 시험군 3 | 시험군 4 | 시험군 1 | 시험군 2 | 시험군 3 | 시험군 4 | |
최대 유연물질 | 0.30% | 0.10% | 0.03% | 0.03% | 0.72% | 0.03% | 0.03% | 0.03% |
총 유연물질 | 1.11% | 0.13% | 0.03% | 0.06% | 3.43% | 0.04% | 0.06% | 0.04% |
Claims (17)
- 수성 매질 중에 (2R,3R,4S)-6-아미노-4-[N-(4-클로로페닐)-N-(1H-이미다졸-2-일메틸)아미노]-3-하이드록시-2-메틸-2-다이메톡시메틸-3,4-다이하이드로-2H-1-벤조피란 또는 이의 약학적으로 허용가능한 염; 안정화제로서 프로필렌글리콜; 및 pH 조절제를 포함하고, 4.0 ∼ 5.0의 pH를 갖는, 용액 형태의 점안제.
- 제1항에 있어서, 상기 (2R,3R,4S)-6-아미노-4-[N-(4-클로로페닐)-N-(1H-이미다졸-2-일메틸)아미노]-3-하이드록시-2-메틸-2-다이메톡시메틸-3,4-다이하이드로-2H-1-벤조피란 또는 이의 약학적으로 허용가능한 염이 3 mg/ml 이상의 농도로 존재하는 것을 특징으로 하는 점안제.
- 제1항에 있어서, 상기 (2R,3R,4S)-6-아미노-4-[N-(4-클로로페닐)-N-(1H-이미다졸-2-일메틸)아미노]-3-하이드록시-2-메틸-2-다이메톡시메틸-3,4-다이하이드로-2H-1-벤조피란 또는 이의 약학적으로 허용가능한 염이 3 ∼ 10 mg/ml의 농도로 존재하는 것을 특징으로 하는 점안제.
- 제1항에 있어서, 상기 프로필렌글리콜이 1 ∼ 20 mg/ml의 농도로 존재하는 것을 특징으로 하는 점안제.
- 제1항에 있어서, 상기 프로필렌글리콜이 5 ∼ 17 mg/ml의 농도로 존재하는 것을 특징으로 하는 점안제.
- 제1항에 있어서, 상기 프로필렌글리콜이 10 ∼ 15 mg/ml의 농도로 존재하는 것을 특징으로 하는 점안제.
- 제1항에 있어서, 4.2 ∼ 4.7의 pH를 갖는 것을 특징으로 하는 점안제.
- 제1항에 있어서, 약 4.5의 pH를 갖는 것을 특징으로 하는 점안제.
- 제1항에 있어서, 안정화 보조제, 완충제, 및 보존제로 이루어진 군으로부터 하나 이상 선택된 첨가제를 추가로 포함하는 점안제.
- 제9항에 있어서, 상기 안정화 보조제가 에틸렌디아민테트라아세트산 또는 이의 염 및 트로메타민으로 이루어진 군으로부터 하나 이상 선택되는 것을 특징으로 하는 점안제.
- 제9항에 있어서, 상기 완충제가 붕사, 붕산, 인산염, 시트르산, 시트르산나트륨 및 아미노카프론산으로 이루어진 군으로부터 하나 이상 선택되는 것을 특징으로 하는 점안제.
- 제9항에 있어서, 상기 보존제가 염화벤잘코늄, 글루콘산클로로헥시딘, 소르빈산류, 클로로부탄올 및 파라벤류로 이루어진 군으로부터 하나 이상 선택되는 것을 특징으로 하는 점안제.
- 제1항에 있어서, 수성 매질 중에 (2R,3R,4S)-6-아미노-4-[N-(4-클로로페닐)-N-(1H-이미다졸-2-일메틸)아미노]-3-하이드록시-2-메틸-2-다이메톡시메틸-3,4-다이하이드로-2H-1-벤조피란 또는 이의 약학적으로 허용가능한 염; 프로필렌글리콜; 에틸렌디아민테트라아세트산 또는 이의 염; 트로메타민; 붕사; 붕산; 염화벤잘코늄; 및 pH 조절제를 포함하는 점안제.
- 제1항에 있어서, 수성 매질 중에 (2R,3R,4S)-6-아미노-4-[N-(4-클로로페닐)-N-(1H-이미다졸-2-일메틸)아미노]-3-하이드록시-2-메틸-2-다이메톡시메틸-3,4-다이하이드로-2H-1-벤조피란 또는 이의 약학적으로 허용가능한 염 3 ∼ 10 mg/ml; 프로필렌글리콜 1 ∼ 20 mg/ml; 에틸렌디아민테트라아세트산 또는 이의 염 0.01 ∼ 1.0 mg/ml; 트로메타민 0.05 ∼ 10.0 mg/ml; 붕사 1.0 ∼ 11.0 mg/ml; 붕산 0.1 ∼ 18.0 mg/ml; 염화벤잘코늄 0.01 ∼ 0.5 mg/ml; 및 pH 조절제를 포함하는 점안제.
- 제1항에 있어서, 수성 매질 중에 (2R,3R,4S)-6-아미노-4-[N-(4-클로로페닐)-N-(1H-이미다졸-2-일메틸)아미노]-3-하이드록시-2-메틸-2-다이메톡시메틸-3,4-다이하이드로-2H-1-벤조피란 또는 이의 약학적으로 허용가능한 염 3 ∼ 10 mg/ml; 프로필렌글리콜 10 ∼ 15 mg/ml; 에틸렌디아민테트라아세트산 또는 이의 염 0.5 mg/ml; 트로메타민 0.35 mg/ml; 붕사 5.8 ∼ 5.9 mg/ml; 붕산 0.5 ∼ 0.6 mg/ml; 염화벤잘코늄 0.05 ∼ 0.15 mg/ml; 및 pH 조절제를 포함하는 점안제.
- 제1항 내지 제15항 중 어느 한 항에 따른 점안제를 차광 용기에 충전하여 얻어진 황반변성의 예방 또는 치료를 위한 의약품.
- 제16항에 있어서, 상기 점안제를 차광 용기에 충전한 다음, 종이 케이스 내에 포장하여 얻어진 황반변성의 예방 또는 치료를 위한 의약품.
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2020125724A RU2778515C2 (ru) | 2018-02-28 | 2019-02-18 | Глазные капли в форме раствора, содержащего производное бензопирана или его фармацевтически приемлемую соль |
US16/975,695 US11771647B2 (en) | 2018-02-28 | 2019-02-18 | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof |
AU2019226830A AU2019226830B2 (en) | 2018-02-28 | 2019-02-18 | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof |
CN201980015549.9A CN111801094B (zh) | 2018-02-28 | 2019-02-18 | 包含苯并吡喃衍生物或其药学上可接受的盐的溶液形式的滴眼剂 |
SG11202007054VA SG11202007054VA (en) | 2018-02-28 | 2019-02-18 | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof |
MX2020008699A MX2020008699A (es) | 2018-02-28 | 2019-02-18 | Gotas para los ojos en forma de solucion que comprende un derivado de benzopirano o una sal farmaceuticamente aceptable del mismo. |
BR112020017497-1A BR112020017497A2 (pt) | 2018-02-28 | 2019-02-18 | Colírios em forma de solução compreendendo derivado de benzopirano ou sal farmaceuticamente aceitável do mesmo |
EP19760870.6A EP3760188B1 (en) | 2018-02-28 | 2019-02-18 | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof |
JP2020545255A JP7160934B2 (ja) | 2018-02-28 | 2019-02-18 | ベンゾピラン誘導体またはその薬学的に許容可能な塩を含む溶液形態の点眼剤 |
CA3089091A CA3089091A1 (en) | 2018-02-28 | 2019-02-18 | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof |
ES19760870T ES2953040T3 (es) | 2018-02-28 | 2019-02-18 | Gotas oculares en forma de solución que comprende derivado de benzopirano o sal farmacéuticamente aceptable de este |
PH12020551194A PH12020551194A1 (en) | 2018-02-28 | 2020-08-06 | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof |
ZA2020/05891A ZA202005891B (en) | 2018-02-28 | 2020-09-23 | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180024470A KR102478553B1 (ko) | 2018-02-28 | 2018-02-28 | 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제 |
KR10-2018-0024470 | 2018-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019168289A1 true WO2019168289A1 (ko) | 2019-09-06 |
Family
ID=67805843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/001894 WO2019168289A1 (ko) | 2018-02-28 | 2019-02-18 | 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제 |
Country Status (14)
Country | Link |
---|---|
US (1) | US11771647B2 (ko) |
EP (1) | EP3760188B1 (ko) |
JP (1) | JP7160934B2 (ko) |
KR (1) | KR102478553B1 (ko) |
CN (1) | CN111801094B (ko) |
AU (1) | AU2019226830B2 (ko) |
BR (1) | BR112020017497A2 (ko) |
CA (1) | CA3089091A1 (ko) |
ES (1) | ES2953040T3 (ko) |
MX (1) | MX2020008699A (ko) |
PH (1) | PH12020551194A1 (ko) |
SG (1) | SG11202007054VA (ko) |
WO (1) | WO2019168289A1 (ko) |
ZA (1) | ZA202005891B (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856345A (en) * | 1994-03-15 | 1999-01-05 | Senju Pharmaceutical Co., Ltd. | Method for stabilizing pranoprofen and stable liquid preparation of pranoprofen |
KR20010022113A (ko) * | 1997-07-23 | 2001-03-15 | 오노 야꾸힝 고교 가부시키가이샤 | 주성분으로서 벤조피란 유도체를 함유하는 수성 액체 제약조성물 |
KR100492252B1 (ko) | 2002-08-09 | 2005-05-30 | 한국화학연구원 | 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법 |
KR20120112162A (ko) | 2011-03-30 | 2012-10-11 | 가톨릭대학교 산학협력단 | 황반변성 예방 또는 치료용 약학 조성물 |
US20150031705A1 (en) * | 1999-09-16 | 2015-01-29 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
JP2016501849A (ja) * | 2012-11-15 | 2016-01-21 | タフツ ユニバーシティー | ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10236951A (ja) * | 1996-12-27 | 1998-09-08 | Teika Seiyaku Kk | プラノプロフェン配合点眼剤 |
JP2011011984A (ja) * | 2009-06-30 | 2011-01-20 | Lion Corp | 仮性近視治療薬 |
US9795560B2 (en) * | 2013-02-01 | 2017-10-24 | Ocularis Pharma, Llc | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
-
2018
- 2018-02-28 KR KR1020180024470A patent/KR102478553B1/ko active IP Right Grant
-
2019
- 2019-02-18 MX MX2020008699A patent/MX2020008699A/es unknown
- 2019-02-18 EP EP19760870.6A patent/EP3760188B1/en active Active
- 2019-02-18 ES ES19760870T patent/ES2953040T3/es active Active
- 2019-02-18 WO PCT/KR2019/001894 patent/WO2019168289A1/ko active Application Filing
- 2019-02-18 JP JP2020545255A patent/JP7160934B2/ja active Active
- 2019-02-18 BR BR112020017497-1A patent/BR112020017497A2/pt unknown
- 2019-02-18 SG SG11202007054VA patent/SG11202007054VA/en unknown
- 2019-02-18 AU AU2019226830A patent/AU2019226830B2/en active Active
- 2019-02-18 CN CN201980015549.9A patent/CN111801094B/zh active Active
- 2019-02-18 CA CA3089091A patent/CA3089091A1/en active Pending
- 2019-02-18 US US16/975,695 patent/US11771647B2/en active Active
-
2020
- 2020-08-06 PH PH12020551194A patent/PH12020551194A1/en unknown
- 2020-09-23 ZA ZA2020/05891A patent/ZA202005891B/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856345A (en) * | 1994-03-15 | 1999-01-05 | Senju Pharmaceutical Co., Ltd. | Method for stabilizing pranoprofen and stable liquid preparation of pranoprofen |
KR20010022113A (ko) * | 1997-07-23 | 2001-03-15 | 오노 야꾸힝 고교 가부시키가이샤 | 주성분으로서 벤조피란 유도체를 함유하는 수성 액체 제약조성물 |
US20150031705A1 (en) * | 1999-09-16 | 2015-01-29 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
KR100492252B1 (ko) | 2002-08-09 | 2005-05-30 | 한국화학연구원 | 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법 |
KR20120112162A (ko) | 2011-03-30 | 2012-10-11 | 가톨릭대학교 산학협력단 | 황반변성 예방 또는 치료용 약학 조성물 |
JP2016501849A (ja) * | 2012-11-15 | 2016-01-21 | タフツ ユニバーシティー | ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット |
Also Published As
Publication number | Publication date |
---|---|
SG11202007054VA (en) | 2020-08-28 |
EP3760188B1 (en) | 2023-06-14 |
ZA202005891B (en) | 2022-03-30 |
CA3089091A1 (en) | 2019-02-18 |
CN111801094B (zh) | 2022-11-18 |
AU2019226830B2 (en) | 2024-01-11 |
EP3760188A1 (en) | 2021-01-06 |
JP2021514995A (ja) | 2021-06-17 |
PH12020551194A1 (en) | 2021-08-16 |
EP3760188A4 (en) | 2021-10-20 |
AU2019226830A1 (en) | 2020-08-13 |
US20200405634A1 (en) | 2020-12-31 |
RU2020125724A3 (ko) | 2022-04-29 |
KR20190103710A (ko) | 2019-09-05 |
KR102478553B1 (ko) | 2022-12-16 |
JP7160934B2 (ja) | 2022-10-25 |
US11771647B2 (en) | 2023-10-03 |
EP3760188C0 (en) | 2023-06-14 |
CN111801094A (zh) | 2020-10-20 |
RU2020125724A (ru) | 2022-03-28 |
MX2020008699A (es) | 2020-09-25 |
ES2953040T3 (es) | 2023-11-07 |
BR112020017497A2 (pt) | 2020-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2406499C2 (ru) | Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений | |
TWI833406B (zh) | 含有迪夸弗索(Diquafosol)及陽離子性聚合物之眼科用組合物 | |
EA034839B1 (ru) | Офтальмологический раствор | |
KR101587412B1 (ko) | 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물 | |
KR20060100440A (ko) | 각결막 장해 치료제 | |
KR20010012521A (ko) | 방부 조성물 | |
WO2017142193A1 (ko) | 사이클로스포린과 히알루론산 또는 이의 염을 포함하는 수용액 형태의 안과용 조성물 | |
JP2022003099A (ja) | ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物 | |
WO2018155773A1 (ko) | 폴리에틸렌 글리콜 및 플라보노이드 나노복합체를 유효성분으로 함유하는 안구 건조증 예방 또는 치료용 조성물 | |
CN101278905A (zh) | 含那他霉素的眼用组合物、用途及其制作方法 | |
WO2021049825A1 (ko) | 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법 | |
WO2019168289A1 (ko) | 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제 | |
ES2900524T3 (es) | Métodos para el uso de la 5'-adenosina difosfato de ribosa (ADPR) | |
JP6509244B2 (ja) | 水晶体硬化抑制剤 | |
WO2020175525A1 (ja) | ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物 | |
JP3502574B2 (ja) | 眼感染症治療用眼軟膏剤 | |
WO2012074237A2 (ko) | 도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물 | |
WO2019171260A1 (en) | Pharmaceutical composition of lifitegrast | |
WO2018052185A1 (ko) | 사이클로스포린의 안구필름 제형 | |
US10918725B2 (en) | Ophthalmic composition comprising rebamipide and method for preparing the same | |
WO2017179003A1 (en) | Topical compositions for ophthalmic and otic use | |
US20100113456A1 (en) | Therapeutic agent for corneal disease | |
CN108815119A (zh) | 一种含有盐酸贝西沙星的药物组合物及其制备方法 | |
JPH1192368A (ja) | ベンゾピラン誘導体を主成分とする水性液剤 | |
WO2013055073A2 (ko) | 사이클로스포린 함유 안약 조성물 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19760870 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3089091 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019226830 Country of ref document: AU Date of ref document: 20190218 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020545255 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020125724 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2019760870 Country of ref document: EP Effective date: 20200928 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020017497 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020017497 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200827 |